Nektar Therapeutics' Q3 revenue drops after facility sale

Nektar Therapeutics

06/11/2025 22:35

Overview

Nektar Q3 2025 revenue falls to $11.8 mln from $24.1 mln due to facility sale

Net loss for Q3 2025 was $35.5 mln

Operating costs decreased due to facility sale and lower R&D expenses

Outlook

Nektar expects cash to support operations into Q2 2027

Result Drivers

REVENUE DECLINE - Revenue decreased due to the sale of the Huntsville manufacturing facility, ending product sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$11.79 mln
Q3 EPS
-$1.87
Q3 Net Income
-$35.52 mln
Q3 Income From Operations
-$31.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nektar Therapeutics is $100.00, about 45.7% above its November 5 closing price of $54.26

Press Release: ID:nPn5ZFzgwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)